We send the latest information from SMC Laboratories.
We will be presenting our study on STAM™ mice at the American Association for the Study of Liver Disease…
We are pleased to announce that SMC Laboratories will be exhibiting at The 31st Japan Digestive Disease Week (…
Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Mon…
SMC is proud to announce that Dong-A ST Co., Ltd. (KOR) has published the results of their study using our pre…
The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for 89bio, Inc.'s pegozafermin, a new dru…
We are pleased to announce that SMC Laboratories will be attending the BioJapan 2023 from October 11th (W…
We are pleased to announce that SMC Laboratories will be attending the BioPharm America Partnering Event …
Acute liver failure (ALF) carries a high mortality of approximately 40%, which is caused by virus infections (…
We are pleased to introduce a study on non-alcoholic steatohepatitis (NASH) may promote the development and ex…
Today, we are excited to invite you to join our Webinar that will be taking place on August 18th from 9:30 AM …